Psychopharmacological treatment of psychotic children: A SURVEY

Abstract

Controlled investigations on the psychopharmacological treatment of psychotic children are reviewed. Children with infantile autism might benefit from psychopharmacological medication when they grow older, e.g. above the age of 7 years. Learning might be facilitated when the psychoactive medication is able to inhibit psychotic preoccupations and idiosyncratic reactions. Schizophrenic and manic-depressive psychoses are rarely seen in childhood. A subgroup of the children with infantile autism might develop schizophrenic symptoms. Schizophrenia and manic-depressive psychosis in children are treated as in adults. Special caution must be paid to the toxic effects of imipramine.

Psychopharmacology of autism spectrum disorders: A selective review

“…Campbell et al, 1971). Studies published before 1980 often included a wide variety of severely disturbed children under the umbrella of autism, including those with so-called childhood schizophrenia and bipolar disorder (Fish et al, 1966; Jorgensen, 1979).…”

Schizophrenia in Children: A Review of European Research

“…Michaux et al (1971) conclude that fluphenazine enanthate is effective in adolescent schizophrenia and partially effective in infantile psychosis, but has no effect on psychotic children in the latency period. It has been suggested (Jørgensen 1979) that the pharmacological treatment of schizophrenia in children should follow the guidelines for treatment of adult patients, but that special care must be taken during the treatment of children in pubertal development because of the well-known influence of phenothiazine derivatives on the excretion of prolactin. On the contrary, O’Gorman (1970) states that tranquilizers are very seldom effective in the treatment of childhood schizophrenia, in contrast to their efficacy in adult schizophrenia.…”

Νηπιακος Αυτισμος: Δεδομενα, Συγχρονες Ταξινομησεις Και Μελετη Νευροχημικων Παραμετρων

“…Η θειοριδαζίνη παρόλο που έχει χρησιμοποιηθεί πολύ στην πράξη έχει ελεγχθεί με μελέτες λιγότερο. Το ίδιο ισχύει και για την περιφεναζίνη από τις φαινοθειαζίνες, όπως και για τη θειοθιξένη από τα θειοξανθένια (Jorgensen 1979). Οι γνωστές παρενέργειες των νευροληπτικών προκύπτουν και εδώ, φαινόμενα όψιμης δυσκινησίας έχουν παρατηρηθεί και ένα πολύ ενδιαφέρον σύνδρομο κατά την απόσυρση των φαρμάκων έχει περιγραφεί (Engelhardt & Polizos 1978).…”